Surgeries & Interventions

PCI Fizzles in REVIVED Study

PCI

The highly anticipated REVIVED trial found that percutaneous coronary intervention (PCI) does not reduce all-cause mortality or heart failure hospitalization in patients with severe ventricular dysfunction. 

The researchers thought that PCI would improve outcomes in these patients, all of whom had myocardial viability, extensive and stable coronary artery disease, and severe ischaemic left ventricular dysfunction (ejection fraction ≤ 35%). In fact, the researchers selected this patient population because they were the most likely cohort to experience PCI benefits. The authors wanted to “stack the deck” in favor of intervention. 

But when the investigators randomized 700 patients into either PCI or medical therapy groups, and then followed up between 2 and 8.5 years later, they found no clear PCI advantage.  

  • By a median of 3.4 years, 38% of the medical therapy group had either died or experienced heart failure hospitalization.
  • Surprisingly, the percentage was exactly the same in the PCI group (hazard ratio: 0.99).
  • There was also no difference in left ventricular ejection fraction at six and 12 months.
  • By 2 years, quality-of-life scores were not significantly different.

The Takeaway

The authors found no long-term benefit to the more invasive option for patients with stable coronary artery disease and impaired LV systolic function. That’s consistent with other studies showing PCI isn’t always safer or better than medication therapy for people with CAD, although it is the first to demonstrate these findings in this patient population. It might also prompt cardiologists to think twice before offering PCI to patients with ischemic cardiomyopathy.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiac Imaging June 16, 2025

Beyond Hardware: Is AI the Answer to Making Cardiac Imaging more Accessible? June 16, 2025

Sponsored by Philips Healthcare Cardiac imaging has traditionally improved through hardware advances, enabling the speed needed for high-quality images. However, hardware is rapidly reaching its physical limitations in suppressing cardiac motion and represents a large financial investment. Today, software and AI are driving the next leap in cardiac image quality and motion control – offering […]

Cardiology Pharmaceuticals June 12, 2025

FDA Approves a New BP Triple Polypill June 12, 2025

Bringing a more effective BP therapy to the U.S. market, the FDA approved George Medicines’ triple therapy polypill called Widaplik for patients with hypertension, making it the first of its kind to go to market in the U.S. Widaplik’s approval stems from two studies, including one comparing the polypill against placebo as an initial treatment […]

Cardiology Pharmaceuticals June 12, 2025

Pharmacologic Preconditioning to Improve Outcomes in Patients Undergoing Cardiac Surgery  June 12, 2025

The majority of patients undergoing cardiac surgery, especially those on cardiopulmonary bypass (CPB), experience post-operative complications such as new-onset atrial fibrillation (POAF) and acute kidney injury (AKI), largely driven by oxidative stress and inflammation.   Several approaches have been explored to reduce complications following cardiac surgery, however, a clinically meaningful impact has yet to be realized.  […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!